CA-125 monitoring in the management of ovarian cancer

M. Bruzzone, M. Onetto, E. Campora, S. Chiara, C. Oliva, T. Guido, L. Merlini, S. Parodi, G. Bentivoglio, W. Ventrella, M. Paganuzzi, P. Conte, R. Rosso

Research output: Contribution to journalArticlepeer-review


In 100 ovarian cancer patients serum CA-125 was monitored during treatment and follow-up to verify the prognostic value of its pre-surgery marker level and the usefulness of the test for disease monitoring. A low pre-operative CA-125 was not associated with improved survival or progression-free survival. A significant survival advantage was evident for patients in whom the marker had decreased during treatment, compared to patients in whom the antigen remained unchanged or increased. In 40 patients CA-125 was measured before second look laparotomy: the marker was negative in 100% of patients in pathological complete response and in 53.5% of patients with residual disease at second look. A marker increase was evident in 32 of 41 patients with either progressive or recurrent disease, and in 17 patients the CA-125 increase was documented from 1 to 9 months before clinical evidence of progression. The pre-operative level of CA-125 did not appear to be of prognostic value. However, the monitoring of CA-125 during treatment and follow-up can provide a reliable method of assessing response and prognosis. CA-125 monitoring is particularly useful for early detection of recurrence.

Original languageEnglish
Pages (from-to)1353-1360
Number of pages8
JournalAnticancer Research
Issue number5 A
Publication statusPublished - 1990


  • CA-125
  • ovarian cancer
  • tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'CA-125 monitoring in the management of ovarian cancer'. Together they form a unique fingerprint.

Cite this